Twist Bioscience与 Element Biosciences拓展合作，通过共同开发的端到端解决方案，革新下一代测序工作流程-动脉网

Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

PHARMA FOCUS ASIA 等信源发布 2025-05-23 13:27



可切换为仅中文







Twist Bioscience Corporation, a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element’s AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows..

Twist Bioscience Corporation是一家在医疗保健行业生命科学领域中具有核心中型市值增长和价值的公司，而Element Biosciences, Inc.是一家致力于普及先进生命科学解决方案的公司，双方今天宣布扩大合作，以在其AVITI系统和Trinity流动槽中增加Twist的文库制备和靶向富集工作流程。

“This collaboration builds on our existing relationship with Element, which has yielded Twist's on-market Element-native kit and 1-hour fast hybridization Trinity solution. Twist will have exclusive access to develop additional library prep and target enrichment workflows compatible with Element’s Trinity sequencing technology, giving Element customers access to the uniformity, consistency and quality provided by our NGS tools,” said Emily M.

“这次合作建立在我们与Element现有关系的基础上，已经产生了Twist的上市Element原生试剂盒和1小时快速杂交Trinity解决方案。Twist将拥有独家权限，开发与Element的Trinity测序技术兼容的更多文库制备和靶向富集工作流程，使Element客户能够获得我们NGS工具所提供的均匀性、一致性和质量。”Emily M.表示。

Leproust, CEO and co-founder of Twist Bioscience. “This will further advance Twist and Element's shared goal to radically streamline hybrid capture processes both off and on the sequencer. With the expansion of our co-development and commercial efforts, we will be able to further serve critical markets such as agbio, population genomics and clinical research.

Twist Bioscience 的首席执行官兼联合创始人勒普鲁斯特表示：“这将进一步推动 Twist 和 Element 共同实现彻底简化测序仪内外杂交捕获流程的目标。通过扩大我们的共同开发和商业努力，我们将能够进一步服务于农业生物、群体基因组学和临床研究等关键市场。”

Adapting our broadly compatible and innovative NGS workflows to work on Element’s sequencing platform demonstrates the broad applicability and versatility of our NGS products and enables customers flexibility to choose the system that best meets their needs without sacrificing uniformity or quality delivered through the Twist portfolio.”.

将我们广泛兼容且创新的NGS工作流程适应于Element测序平台，展示了我们NGS产品的广泛应用性和多功能性，使客户能够灵活选择最符合其需求的系统，同时不牺牲Twist产品组合所提供的均一性或质量。

'By uniting our revolutionary Trinity workflow for targeted sequencing with Twist's superior library preparation capabilities, we're creating an integrated solution that further catalyzes access to premium life science tools and accelerates scientific discovery across every field,” said Molly He, CEO and co-founder of Element Biosciences.

“通过将我们革命性的Trinity靶向测序工作流程与Twist卓越的文库制备能力相结合，我们正在创建一个集成解决方案，进一步促进获取优质生命科学工具，并加速各个领域的科学发现，”Element Biosciences首席执行官兼联合创始人贺茉莉表示。

“Our partnership with Twist reflects both our companies' drive to remove barriers that have constrained innovation in this space for far too long.'.

“我们与Twist的合作反映了我们两家公司都致力于消除长期以来制约这一领域创新的障碍。”

The collaboration between Twist and Element will enable researchers to access end-to-end workflows from library prep through sequencing on Element’s AVITI platform, which offers high-quality sequencing and flexibility. Under the collaboration, Twist will be the exclusive partner of these new library prep and target enrichment workflows, expanding the existing Trinity offerings beyond exome sequencing and delivering industry-leading performance across key NGS applications.

Twist与Element的合作将使研究人员能够访问从文库制备到在Element的AVITI平台上进行测序的端到端工作流程，该平台提供高质量的测序和灵活性。根据合作协议，Twist将成为这些新的文库制备和目标富集工作流程的独家合作伙伴，将现有的Trinity产品扩展到外显子组测序之外，并在关键的NGS应用中提供行业领先的性能。

Twist and Element will engage in joint commercial and promotional activities to improve customer access to these innovative solutions..

Twist 和 Element 将开展联合商业和推广活动，以改善客户对这些创新解决方案的获取途径。

About Element Biosciences, Inc.

关于Element Biosciences公司

Element Biosciences is a life science company democratizing access to advanced biological tools, driving impactful discoveries to benefit humanity. Through innovating every fundamental element of a biological assay system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries.

Element Biosciences是一家生命科学公司，致力于普及先进生物工具的使用，推动对人类有益的重大发现。通过创新生物分析系统的每一个基本要素，Element为客户提供价格合理的高质量数据和更佳的用户体验，从而加速科学发现。

To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn, X (Twitter), and Facebook..

要了解有关 Element 的更多信息，请访问 www.elementbiosciences.com 并在 LinkedIn、X（Twitter）和 Facebook 上关注我们。

About Twist Bioscience Corporation

关于Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet.

在Twist Bioscience，我们为那些正在让世界变得更美好的客户服务。在医学、农业、工业化学品和国防等领域，通过使用我们的合成DNA工具，我们的客户正在开发改善生活和提升地球可持续性的方法。

The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts..

我们的客户越快取得成功，对我们所有人就越有利，而Twist Bioscience具备独特的优势，能够帮助加速他们的努力。

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead.

我们的创新硅基DNA合成平台为客户提供前所未有的精准度。我们的平台技术克服了低效问题，实现了经济高效、快速、精准、高通量的合成、测序和治疗发现，同时提供客户所需的工具质量和数量，帮助他们最快地实现未来的机遇。

For more information about our products and services, please visit www.twistbioscience.com..

有关我们产品和服务的更多信息，请访问 www.twistbioscience.com。

关注我们在领英 | X | YouTube | Instagram | Bluesky

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

Twist Bioscience关于前瞻性声明的法律声明

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

本新闻稿包含前瞻性陈述。除本文所含的历史事实陈述外，所有其他陈述均为前瞻性陈述，反映了管理层根据《1995年私人证券诉讼改革法案》的安全港条款作出的当前信念和期望。

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

前瞻性声明涉及已知和未知的风险、不确定性以及其他重要因素，这些因素可能导致Twist的实际结果、业绩或成就与前瞻性声明中明示或暗示的任何未来结果、业绩或成就存在重大差异。

Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S.

此类风险和不确定性包括但不限于：吸引新客户以及保留现有客户并增加其销售额的能力；Twist实现足够收入以在任何特定时期实现或维持经营活动的正现金流或盈利能力的能力；在必要时获得融资的能力；快速变化的技术和合成生物学领域的激烈竞争可能使Twist正在开发的产品过时或失去竞争力的风险和不确定性；扩展DNA合成生产能力的能力；对关键组件依赖单一供应商的风险；对关键人员的依赖；可能增加Twist成本并延迟商业化的额外法规；美国政策的变化。

trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk fac.

贸易政策和其他可能导致成本增加和供应链中断的贸易行动；以及维持和执行知识产权保护的能力。有关可能导致实际结果与这些前瞻性陈述中表达的结果不同的风险和不确定性描述，以及与Twist业务相关的风险，请参阅Twist的风险因素。

FOR TWIST:

对于扭转：

For Investors:

对于投资者：

Angela Bitting

安吉拉·比廷

SVP, Corporate Affairs

高级副总裁，企业事务部

925-202-6211

abitting@twistbioscience.com

艾比廷@扭力生物科学.com